Allergy D Childrens

Allium Cepa, Dulcamara, Euphrasia Officinalis, Nux Vomica, Pulsatilla, Rosa Damascena, Sabidilla, Sinapis Nigra, Wyethia Helenoides


Genexa Inc.
Human Otc Drug
NDC 69676-0026
Allergy D Childrens also known as Allium Cepa, Dulcamara, Euphrasia Officinalis, Nux Vomica, Pulsatilla, Rosa Damascena, Sabidilla, Sinapis Nigra, Wyethia Helenoides is a human otc drug labeled by 'Genexa Inc.'. National Drug Code (NDC) number for Allergy D Childrens is 69676-0026. This drug is available in dosage form of Tablet, Chewable. The names of the active, medicinal ingredients in Allergy D Childrens drug includes Black Mustard Seed - 12 [hp_X]/1 Euphrasia Stricta - 12 [hp_X]/1 Onion - 12 [hp_X]/1 Pulsatilla Pratensis - 12 [hp_X]/1 Rosa Damascena Flowering Top - 6 [hp_X]/1 Schoenocaulon Officinale Seed - 12 [hp_X]/1 Solanum Dulcamara Stem - 12 [hp_X]/1 Strychnos Nux-vomica Seed - 12 [hp_X]/1 Wyethia Helenioides Root - 12 [hp_X]/1 . The currest status of Allergy D Childrens drug is Active.

Drug Information:

Drug NDC: 69676-0026
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Allergy D Childrens
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Allium Cepa, Dulcamara, Euphrasia Officinalis, Nux Vomica, Pulsatilla, Rosa Damascena, Sabidilla, Sinapis Nigra, Wyethia Helenoides
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Genexa Inc.
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Tablet, Chewable
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:BLACK MUSTARD SEED - 12 [hp_X]/1
EUPHRASIA STRICTA - 12 [hp_X]/1
ONION - 12 [hp_X]/1
PULSATILLA PRATENSIS - 12 [hp_X]/1
ROSA DAMASCENA FLOWERING TOP - 6 [hp_X]/1
SCHOENOCAULON OFFICINALE SEED - 12 [hp_X]/1
SOLANUM DULCAMARA STEM - 12 [hp_X]/1
STRYCHNOS NUX-VOMICA SEED - 12 [hp_X]/1
WYETHIA HELENIOIDES ROOT - 12 [hp_X]/1
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:ORAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: UNAPPROVED HOMEOPATHIC
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 21 Mar, 2016
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 31 May, 2023
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Listing Expiration Date: 18 Jun, 2026
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Genexa Inc.
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
NUI:N0000185371
N0000175629
N0000184306
M0000728
M0006342
M0022575
N0000185375
N0000185001
M0016962
M0516536
Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT).
UNII:8LTY55LQ8D
C9642I91WL
492225Q21H
8E272251DI
21W82Q764G
6NAF1689IO
IR986LE7DF
269XH13919
J10PD1AQ0N
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class EPC:Non-Standardized Food Allergenic Extract [EPC]
Non-Standardized Plant Allergenic Extract [EPC]
Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`.
Pharmacologic Class PE:Increased Histamine Release [PE]
Cell-mediated Immunity [PE]
Increased IgG Production [PE]
Physiologic effect or pharmacodynamic effect—tissue, organ, or organ system level functional activity—of the drug’s established pharmacologic class. Takes the form of the effect, followed by `[PE]` (such as `Increased Diuresis [PE]` or `Decreased Cytokine Activity [PE]`.
Pharmacologic Class CS:Allergens [CS]
Dietary Proteins [CS]
Vegetable Proteins [CS]
Plant Proteins [CS]
Seed Storage Proteins [CS]
Chemical structure classification of the drug product’s pharmacologic class. Takes the form of the classification, followed by `[Chemical/Ingredient]` (such as `Thiazides [Chemical/Ingredient]` or `Antibodies, Monoclonal [Chemical/Ingredient].
Pharmacologic Class:Allergens [CS]
Cell-mediated Immunity [PE]
Dietary Proteins [CS]
Increased Histamine Release [PE]
Increased IgG Production [PE]
Non-Standardized Food Allergenic Extract [EPC]
Non-Standardized Plant Allergenic Extract [EPC]
Plant Proteins [CS]
Seed Storage Proteins [CS]
Vegetable Proteins [CS]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
69676-0026-11 BOTTLE, PLASTIC in 1 CARTON (69676-0026-1) / 60 TABLET, CHEWABLE in 1 BOTTLE, PLASTIC21 Mar, 201631 May, 2023No
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Purpose sneezing and runny nose cough and runny eyes irritated eyes, itchy eyes and watery eyes itchy nose and throat, sinus pain allergic headache and loss of smell hay fever symptoms burning in nose, throat and eyes runny nose and sinus pressure nasal congestion

Product Elements:

Allergy d childrens allium cepa, dulcamara, euphrasia officinalis, nux vomica, pulsatilla, rosa damascena, sabidilla, sinapis nigra, wyethia helenoides acai euphrasia stricta euphrasia stricta pulsatilla pratensis pulsatilla pratensis schoenocaulon officinale seed schoenocaulon officinale seed solanum dulcamara stem solanum dulcamara stem onion onion strychnos nux-vomica seed strychnos nux-vomica seed rosa damascena flowering top rosa damascena flowering top black mustard seed black mustard seed wyethia helenioides root wyethia helenioides root carnauba wax maltodextrin rice bran dextrose off-white g

Indications and Usage:

Uses* addresses symptoms associated with hay fever or other upper respiratory allergies, such as: irritated eyes sinus pain sneezing runny nose nasal congestion itchy throat & nose

Warnings:

Warnings

Dosage and Administration:

Directions for best results, use at the first sign of symptoms and continue to use as needed. children 3-11 years of age: chew 2 tablets at the onset of symptoms. do not swallow whole. repeat every 6-8 hours as needed. children under 3 years of age: ask a doctor before use.

Stop Use:

Stop use and ask a doctor if symptoms persist for more than 3 days or worsen.

Package Label Principal Display Panel:

Children's genexa® the healthier medicine® ndc 69676-0026-1 ages 3+ non-drowsy / organic allergy-d tm allergy & decongestant* sneezing & runny nose itchy, watery eyes nasal congestion itchy nose & throat* 60 chewable tablets homeopathic organic acai berry flavor usda organic non gmo verified project allergy d child_20181129


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.